Bryant C Sheh, MD
Hematology/Oncology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Eden Medical Center · Mills-Peninsula Medical Center · Stanford Health Care · Sutter Roseville Medical Center · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sheh’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A106904 · Current
Licensed to practise in California · since 2009 · expires 2027-03-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$3,367,532
Medicare paid this office $3,367,532 for 668 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 16 | $787,615 | None |
| Injection, denosumab, 1 mg | 75 | $138,066 | None |
| Administration of chemotherapy into vein, 1 hour or less | 97 | $65,354 | $139 |
| Return visit (30+ min) | 267 | $64,426 | $116 |
| Long return visit (40+ min) | 73 | $32,853 | $165 |
See all 37 services
| Injection, pembrolizumab, 1 mg | 16 | $787,615 | None |
| Injection, denosumab, 1 mg | 75 | $138,066 | None |
| Administration of chemotherapy into vein, 1 hour or less | 97 | $65,354 | $139 |
| Return visit (30+ min) | 267 | $64,426 | $116 |
| Long return visit (40+ min) | 73 | $32,853 | $165 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 12 | $32,074 | $16 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $17,956 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 127 | $17,545 | $65 |
| Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 11 | $14,315 | $10 |
| New patient visit (45+ min) | 91 | $13,487 | $148 |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $8,780 | $66 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $7,089 | $76 |
| Short return visit (20+ min) | 78 | $7,072 | $77 |
| Injection of additional new drug or substance into vein | 55 | $4,738 | $16 |
| Administration of chemotherapy into vein, each additional hour | 43 | $4,606 | $29 |
| Injection of drug or substance under skin or into muscle | 128 | $4,548 | $14 |
| Injection, iron dextran, 50 mg | 14 | $4,173 | None |
| Injection of drug or substance into vein | 51 | $3,054 | $36 |
| Administration of additional new drug or substance into vein using push technique | 15 | $3,010 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | $2,900 | $29 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $2,700 | $37 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $2,394 | $21 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $2,109 | $29 |
| Collection of blood sample from implanted device | 14 | $1,680 | $28 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 53 | $1,637 | $15 |
| Injection, zoledronic acid, 1 mg | 62 | $1,614 | None |
| Injection, leucovorin calcium, per 50 mg | 11 | $1,093 | None |
| Injection, fosaprepitant, 1 mg | 16 | $880 | None |
| Injection, fluorouracil, 500 mg | 12 | $716 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 20 | $643 | $19 |
| Infusion into a vein for hydration, each additional hour | 16 | $633 | $12 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $338 | $24 |
| Infusion, normal saline solution, 250 cc | 150 | $184 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $147 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 35 | $142 | None |
| Infusion, normal saline solution , 1000 cc | 14 | $56 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $52 | None |
Who their Medicare patients are
668 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 17% · Women 65% · Also on Medicaid 18% · Health risk score 1.57. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 71% · Cancer 38% · Diabetes 36% · Chronic kidney disease 28% · Coronary heart disease 27% · Atrial fibrillation 18% · Depression 15% · Heart failure 14% · COPD 10% · Dementia 7% · Stroke 3%.
The office billed $11,045,948, Medicare allowed $4,233,790 and paid $3,367,532; for 184,581 services of 152 kinds; $3,107,591 of it was for drugs given in the office and $259,942 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 668 | 184,581 | 76 | 1.57 | $11,045,948 | $3,367,532 |
| 2023 | 655 | 161,479 | 76 | 1.47 | $8,819,477 | $2,460,650 |
| 2022 | 653 | 182,428 | 76 | 1.53 | $9,004,693 | $2,786,747 |
| 2021 | 506 | 135,322 | 75 | 1.61 | $8,694,062 | $2,944,448 |
| 2020 | 427 | 120,333 | 75 | 1.75 | $7,840,399 | $2,508,513 |
| 2019 | 431 | 115,188 | 74 | 1.64 | $6,274,299 | $2,010,846 |
| 2018 | 380 | 98,034 | 74 | 1.68 | $4,287,814 | $1,359,471 |
| 2017 | 518 | 59,534 | 75 | 1.92 | $2,951,916 | $869,474 |
| 2016 | 412 | 1,719 | 76 | 2.04 | $344,069 | $118,865 |
| 2015 | 370 | 40,024 | 76 | 1.82 | $2,749,065 | $664,603 |
| 2014 | 205 | 12,132 | 77 | 1.71 | $1,039,520 | $261,397 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 41 services
| Injection, pembrolizumab, 1 mg | 14 | $467,070 | None |
| Injection, denosumab, 1 mg | 76 | $140,008 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $124,449 | None |
| Administration of chemotherapy into vein, 1 hour or less | 97 | $61,771 | $142 |
| Return visit (30+ min) | 245 | $57,871 | $115 |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $51,232 | None |
| Injection, golimumab, 1 mg, for intravenous use | 12 | $41,242 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 12 | $40,948 | $22 |
| Long return visit (40+ min) | 48 | $24,674 | $168 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 125 | $20,880 | $67 |
| New patient visit (45+ min) | 101 | $14,750 | $146 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $13,096 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $9,806 | $69 |
| Short return visit (20+ min) | 95 | $8,403 | $74 |
| Administration of chemotherapy into vein, each additional hour | 50 | $6,815 | $29 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 12 | $6,070 | $6 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $6,037 | $77 |
| Injection of drug or substance under skin or into muscle | 143 | $5,258 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $4,857 | $108 |
| Administration of additional new drug or substance into vein using push technique | 14 | $4,311 | $59 |
| Injection of additional new drug or substance into vein | 48 | $4,246 | $16 |
| Injection of drug or substance into vein | 60 | $4,233 | $38 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 31 | $3,614 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 21 | $3,441 | $21 |
| Collection of blood sample from implanted device | 24 | $2,816 | $29 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $2,679 | $36 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $2,127 | $177 |
| Injection, zoledronic acid, 1 mg | 60 | $2,022 | None |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $1,937 | $34 |
| Infusion into a vein for hydration, each additional hour | 32 | $1,349 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 20 | $1,288 | $20 |
| Injection, fosaprepitant, 1 mg | 19 | $1,191 | None |
| Irrigation of implanted venous access drug delivery device | 14 | $723 | $27 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $675 | $24 |
| Injection, carboplatin, 50 mg | 11 | $449 | None |
| Infusion, normal saline solution, 250 cc | 162 | $218 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 36 | $170 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 34 | $143 | None |
| Infusion, normal saline solution , 1000 cc | 16 | $103 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $58 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $42 | None |
2022: 30 services
| Injection, pembrolizumab, 1 mg | 15 | $614,935 | None |
| Injection, denosumab, 1 mg | 90 | $129,252 | None |
| Administration of chemotherapy into vein, 1 hour or less | 91 | $64,115 | $145 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 13 | $61,016 | $41 |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $57,723 | None |
| Return visit (30+ min) | 209 | $52,489 | $115 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 139 | $25,894 | $69 |
| Long return visit (40+ min) | 48 | $20,288 | $156 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 15 | $17,660 | $6 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $16,838 | None |
| New patient visit (45+ min) | 83 | $12,210 | $147 |
| Short return visit (20+ min) | 118 | $11,304 | $77 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $9,747 | $70 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $7,277 | $80 |
| Injection of drug or substance under skin or into muscle | 149 | $6,751 | $14 |
| Administration of chemotherapy into vein, each additional hour | 50 | $5,704 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 31 | $5,579 | $31 |
| Injection of additional new drug or substance into vein | 51 | $5,136 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 20 | $3,343 | $21 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $3,055 | $34 |
| Collection of blood sample from implanted device | 19 | $2,424 | $29 |
| Injection, zoledronic acid, 1 mg | 65 | $2,150 | None |
| Injection of drug or substance into vein | 28 | $1,598 | $41 |
| Injection, fosaprepitant, 1 mg | 17 | $1,510 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 22 | $692 | $22 |
| Injection, carboplatin, 50 mg | 11 | $610 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 29 | $134 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $121 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 12 | $117 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $79 | None |
2021: 32 services
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $62,348 | None |
| Administration of chemotherapy into vein, 1 hour or less | 77 | $59,983 | $155 |
| Injection, denosumab, 1 mg | 19 | $54,398 | None |
| Return visit (30+ min) | 209 | $44,282 | $112 |
| Long return visit (40+ min) | 74 | $40,842 | $166 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 86 | $20,313 | $76 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $18,904 | None |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 11 | $13,291 | $7 |
| Short return visit (20+ min) | 105 | $9,909 | $73 |
| New patient visit (45+ min) | 55 | $8,300 | $151 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $7,781 | $75 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $5,880 | $33 |
| Administration of chemotherapy into vein, each additional hour | 38 | $5,364 | $32 |
| Injection of additional new drug or substance into vein | 55 | $4,460 | $17 |
| Injection of drug or substance under skin or into muscle | 70 | $4,137 | $14 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,991 | $64 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $3,820 | $34 |
| Injection, iron dextran, 50 mg | 14 | $3,478 | None |
| Collection of blood sample from implanted device | 21 | $2,685 | $28 |
| Injection, zoledronic acid, 1 mg | 52 | $2,433 | None |
| Injection, fosaprepitant, 1 mg | 18 | $2,310 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,776 | $93 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,340 | $61 |
| Injection of drug or substance into vein | 25 | $1,317 | $42 |
| New patient visit (30+ min) | 13 | $1,235 | $95 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $953 | $23 |
| Irrigation of implanted venous access drug delivery device | 11 | $743 | $30 |
| Injection, carboplatin, 50 mg | 14 | $670 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 36 | $157 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 38 | $146 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $44 | None |
| Infusion, normal saline solution, 250 cc | 16 | $10 | None |
2020: 30 services
| Injection, pembrolizumab, 1 mg | 11 | $359,784 | None |
| Administration of chemotherapy into vein, 1 hour or less | 68 | $49,268 | $148 |
| Return visit (30+ min) | 146 | $41,766 | $97 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 77 | $17,076 | $74 |
| Short return visit (20+ min) | 134 | $13,333 | $63 |
| Long return visit (40+ min) | 37 | $8,340 | $137 |
| Administration of chemotherapy into vein, each additional hour | 46 | $7,250 | $31 |
| New patient visit (45+ min) | 46 | $6,956 | $151 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $6,509 | $72 |
| Administration of additional new drug or substance into vein using push technique | 18 | $5,154 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 39 | $5,052 | $32 |
| Injection of additional new drug or substance into vein | 51 | $4,648 | $17 |
| Injection, iron dextran, 50 mg | 15 | $4,287 | None |
| Injection of drug or substance under skin or into muscle | 41 | $3,564 | $14 |
| New patient visit (30+ min) | 37 | $3,439 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $3,190 | $22 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $2,019 | $33 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,829 | $73 |
| Injection, zoledronic acid, 1 mg | 33 | $1,503 | None |
| Collection of blood sample from implanted device | 14 | $1,287 | $26 |
| Irrigation of implanted venous access drug delivery device | 11 | $1,092 | $24 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $1,039 | $23 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $714 | $45 |
| Injection of drug or substance into vein | 17 | $670 | $35 |
| Injection, carboplatin, 50 mg | 11 | $336 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $196 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $133 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $51 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $42 | None |
| Unclassified drugs | 11 | $10 | None |
2019: 27 services
| Injection, rituximab, 10 mg | 12 | $161,399 | None |
| Return visit (30+ min) | 178 | $46,709 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 68 | $44,748 | $143 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $16,688 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 74 | $16,617 | $74 |
| Short return visit (20+ min) | 164 | $15,465 | $66 |
| Long return visit (40+ min) | 41 | $8,835 | $130 |
| New patient visit (45+ min) | 52 | $7,694 | $148 |
| Injection of additional new drug or substance into vein | 53 | $6,153 | $17 |
| Administration of chemotherapy into vein, each additional hour | 34 | $5,131 | $31 |
| Injection of drug or substance under skin or into muscle | 53 | $4,752 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $4,311 | $71 |
| Administration of additional new drug or substance into vein using push technique | 15 | $3,825 | $61 |
| Injection, iron dextran, 50 mg | 13 | $3,390 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 28 | $2,534 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $1,996 | $21 |
| New patient visit (30+ min) | 22 | $1,944 | $88 |
| Injection, zoledronic acid, 1 mg | 35 | $1,646 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $1,231 | $32 |
| Injection of drug or substance into vein | 19 | $1,084 | $40 |
| Collection of blood sample from implanted device | 13 | $808 | $25 |
| Irrigation of implanted venous access drug delivery device | 12 | $596 | $25 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $594 | $23 |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $178 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $152 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $50 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $38 | None |
2018: 23 services
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $90,911 | None |
| Return visit (30+ min) | 224 | $54,064 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 53 | $28,931 | $146 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 51 | $12,480 | $73 |
| New patient visit (45+ min) | 58 | $7,638 | $132 |
| Short return visit (20+ min) | 79 | $6,319 | $63 |
| Injection of additional new drug or substance into vein | 49 | $5,994 | $18 |
| Injection of drug or substance under skin or into muscle | 46 | $5,782 | $20 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $4,320 | $70 |
| Long return visit (40+ min) | 24 | $3,096 | $119 |
| Administration of chemotherapy into vein, each additional hour | 30 | $2,547 | $31 |
| Injection, iron sucrose, 1 mg | 12 | $1,613 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 15 | $1,446 | $31 |
| Injection of drug or substance into vein | 20 | $1,275 | $42 |
| New patient visit (30+ min) | 16 | $1,268 | $79 |
| Injection, zoledronic acid, 1 mg | 21 | $1,136 | None |
| Collection of blood sample from implanted device | 11 | $982 | $25 |
| Injection, paclitaxel, 1 mg | 14 | $794 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $341 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $106 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 19 | $73 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $42 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $31 | None |
2017: 20 services
| Return visit (30+ min) | 262 | $39,697 | $87 |
| Administration of chemotherapy into vein, 1 hour or less | 31 | $17,682 | $137 |
| Long return visit (40+ min) | 72 | $10,988 | $107 |
| New patient visit (45+ min) | 75 | $10,499 | $140 |
| Short return visit (20+ min) | 160 | $7,752 | $39 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $7,614 | $69 |
| Injection of drug or substance under skin or into muscle | 37 | $3,880 | $25 |
| Injection of additional new drug or substance into vein | 24 | $3,131 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $3,039 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,163 | $180 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $2,094 | $18 |
| Administration of chemotherapy into vein, each additional hour | 15 | $1,645 | $27 |
| Biopsy of bone marrow | 11 | $1,468 | $133 |
| Injection, zoledronic acid, 1 mg | 16 | $1,201 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 12 | $839 | $30 |
| Influenza vaccine split virus, preservative free | 17 | $750 | $44 |
| Administration of influenza virus vaccine | 19 | $591 | $31 |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $62 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $46 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 14 | $32 | None |
2016: 9 services
| Long return visit (40+ min) | 150 | $41,076 | $94 |
| Return visit (30+ min) | 176 | $26,416 | $66 |
| Short return visit (20+ min) | 250 | $25,916 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $8,981 | $93 |
| New patient visit (60+ min) | 51 | $6,702 | $131 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $5,408 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,479 | $64 |
| Biopsy of bone marrow | 14 | $966 | $69 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 14 | $112 | $8 |
2015: 23 services
| Injection, rituximab, 100 mg | 11 | $132,988 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $64,645 | None |
| Long return visit (40+ min) | 60 | $20,076 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $19,454 | $92 |
| Short return visit (20+ min) | 163 | $19,082 | $60 |
| Long return visit (40+ min) | 68 | $18,137 | $99 |
| Return visit (30+ min) | 91 | $13,498 | $92 |
| Administration of chemotherapy into vein, 1 hour or less | 27 | $13,431 | $137 |
| Short return visit (20+ min) | 158 | $11,967 | $45 |
| Return visit (30+ min) | 99 | $10,299 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,705 | $179 |
| New patient visit (60+ min) | 42 | $7,375 | $176 |
| New patient visit (60+ min) | 42 | $6,248 | $149 |
| Injection of drug or substance under skin or into muscle | 38 | $5,262 | $25 |
| Administration of chemotherapy into vein, each additional hour | 14 | $2,597 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 17 | $2,549 | $30 |
| Biopsy of bone marrow | 12 | $1,677 | $140 |
| Injection of additional new drug or substance into vein | 21 | $1,558 | $23 |
| Drawing of blood for a medical problem | 11 | $1,492 | $88 |
| New patient visit (45+ min) | 11 | $1,261 | $115 |
| Infusion into a vein for hydration, each additional hour | 12 | $486 | $15 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 11 | $125 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $95 | None |
2014: 9 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17 | $45,314 | None |
| Short return visit (20+ min) | 144 | $19,569 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $7,763 | $92 |
| New patient visit (60+ min) | 32 | $6,029 | $188 |
| Return visit (30+ min) | 36 | $4,604 | $100 |
| Injection of drug or substance under skin or into muscle | 27 | $3,436 | $25 |
| Long return visit (40+ min) | 13 | $3,067 | $133 |
| Drawing of blood for a medical problem | 12 | $2,159 | $103 |
| Short return visit | 12 | $623 | $42 |
Medicaid work
$7 in 2022
Medicaid paid $7 for 18 billed services this clinician did in 2022, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 18 | $7 |
| 2022 | 18 | 1 | 13 | $7 |
Drugs they prescribed that Part D paid
$3,123,233
Pharmacies billed $3,123,233 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (12 of 1,276) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
954 generic and 322 brand-name prescriptions · $3,123,233 in drug cost · 54 antibiotic prescriptions to 23 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 45 | $558,931 | $12,421 |
| Lenalidomide | 26 | $287,466 | $11,056 |
| Verzenio | 17 | $247,999 | $14,588 |
| Imbruvica | 15 | $247,125 | $16,475 |
| Brukinsa | 16 | $230,208 | $14,388 |
See all 30 drugs
| Xtandi | 45 | $558,931 | $12,421 |
| Lenalidomide | 26 | $287,466 | $11,056 |
| Verzenio | 17 | $247,999 | $14,588 |
| Imbruvica | 15 | $247,125 | $16,475 |
| Brukinsa | 16 | $230,208 | $14,388 |
| Tagrisso | 14 | $222,998 | $15,928 |
| Sprycel | 14 | $161,629 | $11,545 |
| Nucala | 12 | $124,153 | $10,346 |
| Eliquis | 70 | $80,303 | $1,147 |
| Venclexta | 18 | $47,900 | $2,661 |
| Xarelto | 15 | $23,148 | $1,543 |
| Exemestane | 20 | $4,374 | $219 |
| Anastrozole | 155 | $3,578 | $23 |
| Letrozole | 50 | $2,089 | $42 |
| Acyclovir | 48 | $1,328 | $28 |
| Ondansetron | 52 | $1,196 | $23 |
| Tamoxifen Citrate | 37 | $1,001 | $27 |
| Dexamethasone | 51 | $761 | $15 |
| Raloxifene | 14 | $628 | $45 |
| Prochlorperazine Maleate | 60 | $570 | $10 |
| Gabapentin | 30 | $491 | $16 |
| Lidocaine-Prilocaine | 18 | $234 | $13 |
| Timolol Maleate | 11 | $218 | $20 |
| Allopurinol | 14 | $217 | $15 |
| Prednisone | 35 | $199 | $6 |
| Potassium Chloride | 13 | $114 | $9 |
| Alendronate | 15 | $80 | $5 |
| Omeprazole | 11 | $75 | $7 |
| Sulfamethoxazole-Trimethoprim | 20 | $60 | $3 |
| Mirtazapine | 15 | $58 | $4 |
Year by year
| 2024 | 1,276 | 216 | 1% (12) | 25% | $3,123,233 |
| 2023 | 993 | 176 | 2% (21) | 30% | $3,080,882 |
| 2022 | 1,108 | 165 | 2% (25) | 25% | $2,472,215 |
| 2021 | 1,124 | 154 | 5% (58) | None | $2,602,990 |
| 2020 | 1,074 | 154 | 4% (41) | 26% | $1,987,467 |
| 2019 | 809 | 148 | 5% (37) | 23% | $1,389,620 |
| 2018 | 855 | 108 | None | 27% | $1,854,486 |
| 2017 | 851 | 199 | 7% (55) | 21% | $1,207,191 |
| 2016 | 1,298 | 196 | 12% (149) | None | $1,188,349 |
| 2015 | 818 | 150 | 8% (64) | None | $506,519 |
| 2014 | 214 | 68 | 12% (26) | 20% | $256,832 |
| 2013 | 71 | 16 | 25% (18) | 24% | $57,206 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 30 drugs
| Xtandi | 39 | $476,571 | $12,220 |
| Imbruvica | 29 | $440,435 | $15,187 |
| Jakafi | 13 | $248,167 | $19,090 |
| Tagrisso | 13 | $235,974 | $18,152 |
| Ibrance | 13 | $217,939 | $16,765 |
| Promacta | 11 | $211,739 | $19,249 |
| Sprycel | 15 | $154,654 | $10,310 |
| Lenalidomide | 11 | $144,639 | $13,149 |
| Creon | 12 | $57,864 | $4,822 |
| Inrebic | 13 | $56,726 | $4,364 |
| Eliquis | 36 | $41,579 | $1,155 |
| Imatinib Mesylate | 14 | $38,805 | $2,772 |
| Xarelto | 21 | $34,714 | $1,653 |
| Venclexta | 18 | $28,968 | $1,609 |
| Entecavir | 14 | $14,888 | $1,063 |
| Abiraterone Acetate | 11 | $10,305 | $937 |
| Letrozole | 48 | $6,371 | $133 |
| Anastrozole | 123 | $4,622 | $38 |
| Raloxifene | 11 | $1,703 | $155 |
| Tamoxifen Citrate | 36 | $1,336 | $37 |
| Acyclovir | 25 | $811 | $32 |
| Dexamethasone | 34 | $652 | $19 |
| Prochlorperazine Maleate | 38 | $370 | $10 |
| Gabapentin | 21 | $333 | $16 |
| Hydrocodone-Acetaminophen | 11 | $326 | $30 |
| Ondansetron | 28 | $311 | $11 |
| Omeprazole | 11 | $273 | $25 |
| Prednisone | 26 | $214 | $8 |
| Megestrol Acetate | 11 | $189 | $17 |
| Alendronate | 15 | $138 | $9 |
2022: 35 drugs
| Lenvima | 17 | $382,543 | $22,503 |
| Erleada | 23 | $310,562 | $13,503 |
| Imbruvica | 22 | $296,529 | $13,479 |
| Revlimid | 13 | $236,281 | $18,175 |
| Xtandi | 24 | $229,404 | $9,559 |
| Jakafi | 12 | $207,884 | $17,324 |
| Sprycel | 11 | $178,638 | $16,240 |
| Promacta | 11 | $125,144 | $11,377 |
| Creon | 16 | $69,834 | $4,365 |
| Inrebic | 11 | $61,345 | $5,577 |
| Eliquis | 56 | $49,340 | $881 |
| Imatinib Mesylate | 12 | $30,161 | $2,513 |
| Xarelto | 18 | $24,133 | $1,341 |
| Deferasirox | 11 | $20,456 | $1,860 |
| Abiraterone Acetate | 26 | $13,489 | $519 |
| Anastrozole | 80 | $3,211 | $40 |
| Dronabinol | 11 | $1,900 | $173 |
| Letrozole | 34 | $1,629 | $48 |
| Acyclovir | 37 | $1,122 | $30 |
| Dexamethasone | 31 | $614 | $20 |
| Tamoxifen Citrate | 25 | $589 | $24 |
| Prochlorperazine Maleate | 67 | $565 | $8 |
| Ondansetron | 33 | $515 | $16 |
| Lidocaine-Prilocaine | 23 | $460 | $20 |
| Pantoprazole | 12 | $326 | $27 |
| Allopurinol | 22 | $305 | $14 |
| Alendronate | 21 | $294 | $14 |
| Prednisone | 45 | $238 | $5 |
| Gabapentin | 15 | $231 | $15 |
| Hydroxyurea | 11 | $142 | $13 |
| Levothyroxine | 13 | $91 | $7 |
| Triamcinolone Acetonide | 13 | $87 | $7 |
| Potassium Chloride | 13 | $64 | $5 |
| Tramadol | 12 | $43 | $4 |
| Amlodipine Besylate | 15 | $21 | $1 |
2021: 28 drugs
| Pomalyst | 19 | $387,593 | $20,400 |
| Erleada | 27 | $331,587 | $12,281 |
| Xtandi | 33 | $237,665 | $7,202 |
| Jakafi | 16 | $214,781 | $13,424 |
| Sprycel | 11 | $191,666 | $17,424 |
| Promacta | 17 | $109,521 | $6,442 |
| Creon | 15 | $49,137 | $3,276 |
| Eliquis | 39 | $27,654 | $709 |
| Anastrozole | 80 | $2,929 | $37 |
| Letrozole | 51 | $1,997 | $39 |
| Dronabinol | 12 | $1,729 | $144 |
| Gabapentin | 29 | $898 | $31 |
| Tamoxifen Citrate | 26 | $807 | $31 |
| Dexamethasone | 37 | $767 | $21 |
| Acyclovir | 47 | $750 | $16 |
| Bicalutamide | 13 | $661 | $51 |
| Prochlorperazine Maleate | 58 | $639 | $11 |
| Clotrimazole | 17 | $446 | $26 |
| Ondansetron | 27 | $429 | $16 |
| Hydroxyurea | 21 | $414 | $20 |
| Alendronate | 22 | $312 | $14 |
| Hydrocodone-Acetaminophen | 20 | $268 | $13 |
| Prednisone | 44 | $237 | $5 |
| Allopurinol | 18 | $193 | $11 |
| Metformin | 13 | $70 | $5 |
| Tramadol | 13 | $70 | $5 |
| Furosemide | 12 | $43 | $4 |
| Amlodipine Besylate | 13 | $33 | $3 |
2020: 28 drugs
| Ibrance | 18 | $235,747 | $13,097 |
| Jakafi | 23 | $235,321 | $10,231 |
| Erleada | 18 | $219,321 | $12,185 |
| Xtandi | 25 | $202,419 | $8,097 |
| Revlimid | 14 | $177,488 | $12,678 |
| Votrient | 13 | $82,402 | $6,339 |
| Venclexta | 13 | $77,934 | $5,995 |
| Xarelto | 23 | $21,086 | $917 |
| Eliquis | 28 | $18,250 | $652 |
| Anastrozole | 97 | $3,376 | $35 |
| Tamoxifen Citrate | 25 | $1,782 | $71 |
| Dronabinol | 13 | $1,723 | $133 |
| Letrozole | 50 | $1,652 | $33 |
| Dexamethasone | 49 | $1,215 | $25 |
| Hydroxyurea | 32 | $904 | $28 |
| Prochlorperazine Maleate | 65 | $765 | $12 |
| Ondansetron | 40 | $718 | $18 |
| Gabapentin | 37 | $678 | $18 |
| Acyclovir | 56 | $662 | $12 |
| Nystatin | 12 | $329 | $27 |
| Prednisone | 30 | $268 | $9 |
| Alendronate | 17 | $257 | $15 |
| Lidocaine-Prilocaine | 14 | $195 | $14 |
| Hydrocodone-Acetaminophen | 19 | $192 | $10 |
| Omeprazole | 11 | $171 | $16 |
| Clotrimazole | 11 | $157 | $14 |
| Allopurinol | 21 | $149 | $7 |
| Tramadol | 11 | $94 | $9 |
2019: 25 drugs
| Imbruvica | 31 | $377,306 | $12,171 |
| Xtandi | 21 | $188,195 | $8,962 |
| Jakafi | 16 | $177,301 | $11,081 |
| Erleada | 11 | $138,230 | $12,566 |
| Eliquis | 20 | $13,789 | $689 |
| Xarelto | 12 | $10,049 | $837 |
| Lyrica | 12 | $5,752 | $479 |
| Anastrozole | 110 | $3,635 | $33 |
| Dronabinol | 11 | $2,505 | $228 |
| Tamoxifen Citrate | 21 | $1,461 | $70 |
| Hydroxyurea | 22 | $950 | $43 |
| Letrozole | 33 | $770 | $23 |
| Nystatin | 13 | $695 | $53 |
| Raloxifene | 11 | $523 | $48 |
| Dexamethasone | 19 | $407 | $21 |
| Acyclovir | 35 | $370 | $11 |
| Prochlorperazine Maleate | 35 | $319 | $9 |
| Ondansetron | 17 | $301 | $18 |
| Gabapentin | 31 | $264 | $9 |
| Lidocaine-Prilocaine | 13 | $216 | $17 |
| Omeprazole | 12 | $206 | $17 |
| Prednisone | 29 | $194 | $7 |
| Allopurinol | 15 | $112 | $7 |
| Hydrocodone-Acetaminophen | 14 | $100 | $7 |
| Tramadol | 16 | $84 | $5 |
2018: 24 drugs
| Revlimid | 25 | $408,923 | $16,357 |
| Zytiga | 31 | $320,078 | $10,325 |
| Imbruvica | 27 | $303,387 | $11,237 |
| Ibrance | 21 | $241,309 | $11,491 |
| Jakafi | 13 | $164,216 | $12,632 |
| Xarelto | 13 | $9,481 | $729 |
| Lyrica | 12 | $5,519 | $460 |
| Exemestane | 12 | $3,089 | $257 |
| Anastrozole | 55 | $1,306 | $24 |
| Nystatin | 17 | $1,142 | $67 |
| Hydroxyurea | 12 | $768 | $64 |
| Letrozole | 46 | $701 | $15 |
| Dexamethasone | 44 | $689 | $16 |
| Tamoxifen Citrate | 14 | $481 | $34 |
| Prednisone | 50 | $457 | $9 |
| Zolpidem | 22 | $407 | $18 |
| Gabapentin | 28 | $353 | $13 |
| Ondansetron | 27 | $292 | $11 |
| Acyclovir | 18 | $282 | $16 |
| Lidocaine-Prilocaine | 13 | $220 | $17 |
| Lorazepam | 30 | $196 | $7 |
| Prochlorperazine Maleate | 32 | $196 | $6 |
| Diphenoxylate-Atropine | 11 | $177 | $16 |
| Omeprazole | 15 | $81 | $5 |
2017: 21 drugs
| Revlimid | 22 | $252,028 | $11,456 |
| Ibrance | 14 | $163,459 | $11,676 |
| Tarceva | 16 | $125,309 | $7,832 |
| Enoxaparin | 13 | $10,049 | $773 |
| Eliquis | 11 | $5,046 | $459 |
| Hydroxyurea | 32 | $1,553 | $49 |
| Anastrozole | 50 | $1,372 | $27 |
| Hydrocodone-Acetaminophen | 33 | $694 | $21 |
| Ondansetron | 31 | $584 | $19 |
| Tamoxifen Citrate | 14 | $557 | $40 |
| Letrozole | 36 | $341 | $9 |
| Acyclovir | 25 | $317 | $13 |
| Gabapentin | 16 | $289 | $18 |
| Nystatin | 11 | $283 | $26 |
| Dexamethasone | 40 | $270 | $7 |
| Prednisone | 33 | $245 | $7 |
| Prochlorperazine Maleate | 30 | $224 | $7 |
| Triamcinolone Acetonide | 14 | $210 | $15 |
| Lorazepam | 30 | $169 | $6 |
| Zolpidem | 15 | $167 | $11 |
| Amlodipine Besylate | 17 | $93 | $5 |
2016: 33 drugs
| Revlimid | 27 | $346,361 | $12,828 |
| Tarceva | 26 | $182,956 | $7,037 |
| Imbruvica | 11 | $114,236 | $10,385 |
| Enoxaparin | 27 | $36,388 | $1,348 |
| Promacta | 14 | $35,982 | $2,570 |
| Hydroxyurea | 55 | $1,802 | $33 |
| Anastrozole | 65 | $1,705 | $26 |
| Ondansetron | 51 | $1,628 | $32 |
| Hydrocodone-Acetaminophen | 52 | $1,198 | $23 |
| Gabapentin | 51 | $1,100 | $22 |
| Fentanyl | 17 | $1,056 | $62 |
| Oxycodone | 24 | $934 | $39 |
| Potassium Chloride | 18 | $798 | $44 |
| Morphine Sulfate Er | 18 | $737 | $41 |
| Dexamethasone | 67 | $592 | $9 |
| Acyclovir | 38 | $446 | $12 |
| Zolpidem | 21 | $403 | $19 |
| Prochlorperazine Maleate | 51 | $365 | $7 |
| Allopurinol | 21 | $279 | $13 |
| Warfarin | 13 | $267 | $21 |
| Terazosin | 15 | $256 | $17 |
| Lorazepam | 37 | $255 | $7 |
| Diphenoxylate-Atropine | 15 | $253 | $17 |
| Tamsulosin | 11 | $221 | $20 |
| Omeprazole | 21 | $208 | $10 |
| Prednisone | 38 | $203 | $5 |
| Amlodipine Besylate | 27 | $178 | $7 |
| Famotidine | 17 | $114 | $7 |
| Lidocaine Hcl Viscous | 12 | $95 | $8 |
| Levofloxacin | 12 | $83 | $7 |
| Furosemide | 16 | $76 | $5 |
| Azithromycin | 12 | $70 | $6 |
| Generlac | 13 | $60 | $5 |
2015: 19 drugs
| Tarceva | 11 | $73,329 | $6,666 |
| Enoxaparin | 12 | $35,831 | $2,986 |
| Xarelto | 16 | $8,321 | $520 |
| Leukeran | 14 | $7,555 | $540 |
| Midodrine | 14 | $1,730 | $124 |
| Ondansetron | 41 | $1,600 | $39 |
| Hydroxyurea | 49 | $1,328 | $27 |
| Anastrozole | 64 | $1,275 | $20 |
| Morphine Sulfate Er | 16 | $1,195 | $75 |
| Gabapentin | 33 | $488 | $15 |
| Hydrocodone-Acetaminophen | 25 | $436 | $17 |
| Megestrol Acetate | 11 | $425 | $39 |
| Dexamethasone | 44 | $409 | $9 |
| Allopurinol | 25 | $389 | $16 |
| Prochlorperazine Maleate | 40 | $238 | $6 |
| Prednisone | 34 | $217 | $6 |
| Lorazepam | 31 | $189 | $6 |
| Omeprazole | 17 | $188 | $11 |
| Zolpidem | 12 | $158 | $13 |
2014: 4 drugs
| Hydroxyurea | 17 | $693 | $41 |
| Hydrocodone-Acetaminophen | 17 | $190 | $11 |
| Prednisone | 12 | $90 | $7 |
| Dexamethasone | 11 | $88 | $8 |
2013: 1 drug
| Hydrocodone-Acetaminophen | 12 | $150 | $12 |
Money from drug and device companies
$509 in 2025
| 2025 | 15 | 21 | None | $509 |
| 2024 | 5 | 6 | None | $147 |
| 2023 | 1 | 1 | None | $29 |
| 2022 | 2 | 6 | None | $96 |
| 2021 | 1 | 1 | None | $14 |
| 2020 | 1 | 1 | None | $13 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Rybrevant | $73 | 3 payments
|
| Pfizer | Padcev | $59 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $49 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $46 | 2 payments
|
| Tempus AI | Xt Cdx | $37 | 2 payments
|
| Deciphera Pharmaceuticals | Qinlock | $33 | 1 payment
|
See all 21 published payments
| Gilead Sciences | Education · 2025-12-16 | Trodelvy | $12 |
| Rigel Pharmaceuticals | Meals · 2025-12-10 | Tavalisse | $22 |
| Genzyme | Meals · 2025-12-02 | Sarclisa | $27 |
| Pfizer | Meals · 2025-11-26 | Padcev | $25 |
| Janssen Biotech | Meals · 2025-11-25 | Rybrevant | $24 |
| Lilly USA | Meals · 2025-11-24 | None | $22 |
| Deciphera Pharmaceuticals | Meals · 2025-11-18 | Qinlock | $33 |
| GlaxoSmithKline | Meals · 2025-11-12 | Ojjaara | $18 |
| Agios Pharmaceuticals | Meals · 2025-10-13 | Pyrukynd | $28 |
| Merck Sharp & Dohme | Meals · 2025-08-26 | Keytruda | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-25 | Enhertu | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-20 | Iclusig | $28 |
| Tempus AI | Meals · 2025-07-30 | Xt Cdx | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-19 | None | $20 |
| Pfizer | Meals · 2025-06-11 | Padcev | $33 |
| Tempus AI | Meals · 2025-05-29 | Xt Cdx | $17 |
| Merck Sharp & Dohme | Meals · 2025-05-27 | Keytruda | $28 |
| Daiichi Sankyo | Meals · 2025-05-01 | Enhertu | $28 |
| Janssen Biotech | Meals · 2025-03-19 | Erleada | $26 |
| Janssen Biotech | Meals · 2025-02-26 | Rybrevant | $23 |
| Celgene | Meals · 2025-02-12 | None | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $147
| Pfizer | Inlyta | $43 | 2 payments
|
| Janssen Biotech | Rybrevant | $35 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $28 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $21 | 1 payment
|
| Array Biopharma | Xalkori | $20 | 1 payment
|
2023: $29
| Novartis Pharmaceuticals | None | $29 | 1 payment
|
2022: $96
| Acrotech Biopharma | Beleodaq | $64 | 5 payments
|
| Pfizer | Ibrance | $32 | 1 payment
|
2021: $14
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
2020: $13
| Merck Sharp & Dohme | Lenvima | $13 | 1 payment
|
Professional record
- NPI
- 1801092242
- Licence
- CA A106904California A106904: Current · expires 2027-03-31
- Trained
- University of California, San Diego School of Medicine, 2007
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-06-22
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3200 Kearney St., Fremont, CA, 94538 · 325 Distel Cir, Los Altos, CA, 94022